Related references
Note: Only part of the references are listed.Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes
Nobuo Hirotsu et al.
CLINICAL INFECTIOUS DISEASES (2020)
Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains
Liva Checkmahomed et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets
Masaki Imai et al.
NATURE MICROBIOLOGY (2020)
Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study
Akira Watanabe et al.
ANTIVIRAL RESEARCH (2019)
Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019
Emi Takashita et al.
EUROSURVEILLANCE (2019)
Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018
Paulina Koszalka et al.
ANTIVIRAL RESEARCH (2019)
Influenza virus polymerase inhibitors in clinical development
Frederick G. Hayden et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2019)
Baloxavir marboxil: the new influenza drug on the market
Ryan O'Hanlon et al.
CURRENT OPINION IN VIROLOGY (2019)
Antivirals targeting the polymerase complex of influenza viruses
Edin J. Mifsud et al.
ANTIVIRAL RESEARCH (2019)
Molecular Dynamics Simulation reveals the mechanism by which the Influenza Cap-dependent Endonuclease acquires resistance against Baloxavir marboxil
Ryunosuke Yoshino et al.
SCIENTIFIC REPORTS (2019)
Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018
Emi Takashita et al.
EUROSURVEILLANCE (2019)
Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons
Larisa V. Gubareva et al.
EUROSURVEILLANCE (2019)
Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection
Keita Fukao et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019
Emi Takashita et al.
EMERGING INFECTIOUS DISEASES (2019)
Drugs for Influenza Treatment: Is There Significant News?
Nicola Principi et al.
FRONTIERS IN MEDICINE (2019)
Adult influenza A (H3N2) with reduced susceptibility to baloxavir or peramivir cured after switching anti-influenza agents
Masafumi Seki et al.
IDCASES (2019)
Identification of the I38T PA Substitution as a Resistance Marker for Next-Generation Influenza Virus Endonuclease Inhibitors
Jeremy C. Jones et al.
MBIO (2018)
Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil
Shinya Omoto et al.
SCIENTIFIC REPORTS (2018)
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents
Frederick G. Hayden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit
Takeshi Noshi et al.
ANTIVIRAL RESEARCH (2018)
Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil
Emi Takashita et al.
FRONTIERS IN MICROBIOLOGY (2018)
Seasonal Incidence of Symptomatic Influenza in the United States
Jerome I. Tokars et al.
CLINICAL INFECTIOUS DISEASES (2018)
Structural and computational study on inhibitory compounds for endonuclease activity of influenza virus polymerase
Satoshi Fudo et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Current and next generation influenza vaccines: Formulation and production strategies
Peter C. Soema et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2015)
Animal models for influenza virus transmission studies: a historical perspective
Nicole M. Bouvier
CURRENT OPINION IN VIROLOGY (2015)
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Yousuke Furuta et al.
ANTIVIRAL RESEARCH (2013)
Neuraminidase inhibitors for influenza B virus infection: Efficacy and resistance
Andrew J. Burnham et al.
ANTIVIRAL RESEARCH (2013)
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
Jennifer L. McKimm-Breschkin
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2013)
Detection and management of antiviral resistance for influenza viruses
Guy Boivin
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2013)
Mutational Analysis of the Binding Pockets of the Diketo Acid Inhibitor L-742,001 in the Influenza Virus PA Endonuclease
Annelies Stevaert et al.
JOURNAL OF VIROLOGY (2013)
Structural and Biochemical Basis for Development of Influenza Virus Inhibitors Targeting the PA Endonuclease
Rebecca M. DuBois et al.
PLOS PATHOGENS (2012)
Structural Analysis of Specific Metal Chelating Inhibitor Binding to the Endonuclease Domain of Influenza pH1N1 (2009) Polymerase
Eva Kowalinski et al.
PLOS PATHOGENS (2012)
Widespread use of neuraminidase inhibitors in Japan
Norio Sugaya
JOURNAL OF INFECTION AND CHEMOTHERAPY (2011)
Puzzling inefficiency of H5N1 influenza vaccines in Egyptian poultry
Jeong-Ki Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The Polymerase Acidic Protein Gene of Influenza A Virus Contributes to Pathogenicity in a Mouse Model
Min-Suk Song et al.
JOURNAL OF VIROLOGY (2009)
The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit
Alexandre Dias et al.
NATURE (2009)
Eight-plasmid system for rapid generation of influenza virus vaccines
E Hoffmann et al.
VACCINE (2002)
Share Paper
